Operating profit before amortization: acrivon.com (ACRV)

Public company logo of Acrivon Therapeutics, Inc. (ACRV)

Why does Acrivon Therapeutics (ACRV) command such deep confidence from scientists and investors? Acrivon Therapeutics is developing precision oncology for the B2B sector, utilizing protein profiles to predict patient response. This ensures success where conventional methods fail. The EBITDA trend confirms financial stability, and the 0.00 mark records this specific operating profit figure before depreciation and amortization.

Acrivon Therapeutics, Inc. (ACRV) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for Acrivon Therapeutics, Inc. (ACRV)

- market price and analyst price targets:
Stock Price Acrivon Pharma|ACRV - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Acrivon Therapeutics|ACRV - Enterprise Value
- balance sheet net asset value indicators:
Net Asset Value per Share Acrivon Therapeutics|ACRV - Company Book Value|Market-to-Book Ratio acrivon.com|ACRV - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Capital Acrivon Therapeutics|ACRV - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Acrivon Therapeutics Inc|ACRV - Company Total Debt|Debt to Net Assets Ratio Acrivon Therapeutics|ACRV - Company Long-Term Debt|Short-Term Debt Acrivon Therapeutics|Immediate Liquidity Ratio acrivon.com
- earnings and market multiples details:
ACRV - Net Profit|Future Profit Acrivon Therapeutics|ACRV - Price to Earnings Ratio|Projected Price to Earnings Ratio acrivon.com|ACRV - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acrivon Therapeutics|ACRV - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Acrivon Therapeutics|ACRV - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year acrivon.com|ACRV - Net earnings per share growth this year|Expected net earnings per share growth next year Acrivon Therapeutics
Fundamental company valuation:Acrivon Pharma
Original product of Acrivon

For Acrivon Therapeutics (ACRV), which invests accumulated cash into costly oncology research, the EBITDA_Co trend visualizes the dynamics of operating cash flow excluding depreciation and debt service. This indicator measures the business's actual ability to generate cash, allowing investors to assess the risk of capital freeze and the company's liquidity resilience amid macroeconomic pressure or recession.

Competitors of Acrivon Therapeutics (ACRV)

Operating profit EBITDA Novocure NVCR|DRTS - Profit before payment of interest, taxes and amortization|FBIO (fortressbiotech.com) - Operating profit before amortization|ALLR: Operating profit EBITDA